200 Users Online
Treponema Pallidum Tests Market Segmented By Treponema Pallidum Particle Agglutination Assay Test, Fluorescent Treponemal Antibody Absorption Test, Treponema Pallidum Hemagglutination Assay Treponemal test and Venereal Disease Research Laboratory Test, Rapid Plasma Reagin Test, Toluidine Red Unheated Serum Test Non-treponemal tests
Several new techniques and approaches have been developed over the years to achieve laboratory culture of T. pallidum and to determine properties related to its metabolism and gene expression. This has allowed for the culturing of the etiological agent i.e. Treponema pallidum. Syphilis is mainly diagnosed through serological testing, which is the most frequently used approach in the laboratory diagnosis of syphilis. A combination of treponemal and non-treponemal diagnostic tests is used to diagnose active syphilis.
To detect antibodies to T. pallidum proteins, treponema pallidum tests, such as treponema pallidum particle agglutination assay (TP-PA) test and treponema pallidum hemagglutination Assay (TPHA), etc., are commonly used. Non-treponema pallidum tests detect antibodies directed against lipid antigens, possibly from treponema and damaged host cells. Non-treponema pallidum tests, such as Venereal disease research laboratory (VDRL) test, Rapid plasma reagin (RPR) test, Toluidine red unheated serum test (TRUST) etc., are widely performed to determine the positivity of a disease.
The easy availability of various confirmatory diagnostics treponema pallidum tests for detecting the presence of syphilis is expected to fuel the global treponemal pallidum tests market over the forecast period.
Sexually transmitted diseases, such as syphilis, still remain a taboo. This is partly due to lack of knowledge about such diseases. Although there is wide availability of various treatment and diagnostic options in the market for the screening of treponema pallidum, factors, such as social pressure & myths related to STDs, become a major restraint during the treatment procedure.
This is especially so in underdeveloped regions where people affected by sexually transmitted diseases, such as syphilis, do not go for screening and treatment procedures to avoid social stigma.
Due to this particular factor, several people are left untreated and undiagnosed in several parts of world. This is a major factor expected to deter the growth of the treponema pallidum tests market during the forecast period.
Treponema pallidum tests detect the presence of syphilis through antibody tests, which are expensive and are required to be performed frequently, i.e. once in every 3 to 6 months if the individual has acquired a sexually transmitted disease. Moreover, the patient may or may not show any signs of syphilis for several weeks due to the absence of any antibodies or the presence of only a few antibodies, which may lead to false results.
Thus, the high cost associated with treponema pallidum tests is a limiting factor restraining the growth of the treponema pallidum tests market.
Clinicians use multiple sources of information for making a diagnosis. For instance, they use information from various risk assessments, multiple serologic tests, physical examination, medical history of previous syphilis test results and treatment and any history of recently infected partners.
More recently, an increasing number of institutions and laboratories have been moving away from traditional syphilis testing algorithms (initial screening with non-treponemal pallidum tests) and towards reverse algorithms (initial screening with treponema pallidum tests). According to research studies, reverse screening algorithm identifies more patients with syphilis that the traditional screening algorithm. According to the CDC, many laboratories are adopting reverse sequence screening to permit high throughput treponema pallidum tests and reduce time and labor required for syphilis screening.
Reverse algorithm also identifies past infections, which might go undetected using the traditional algorithm. Reverse screening also offers a number of other advantages, such as automated screening on a high-throughput treponema pallidum testing platform and specific screening assay.
Furthermore, reverse screening algorithm detects more cases of early or latent syphilis compared to the traditional screening algorithm. Thus, this particular advancement is expected to boost the growth of the treponema pallidum tests market.
Treponema pallidum is a causative agent of syphilis. Treponema pallidum is a motile spirochete organism of genus T. Syphilis commonly spreads through sexual activity. Treponema pallidum enters the host body by rupturing the squamous epithelial tissue.
Primary syphilis is marked by inflammation and ulceration in genital areas. Further progression of syphilis leads to maculopapular rashes and damages to the central nervous system. Syphilis is screened with various diagnostic treponema pallidum tests, some treponema pallidum tests check for the antibody produced by the bacterium and others treponema pallidum tests check for the genetic material of the etiological agent.
The serological tests most commonly performed to screen syphilis are non-treponemal and treponemal pallidum tests.
The report on the treponema pallidum tests market offers a comprehensive evaluation of the business opportunities in the treponema pallidum tests market along with insights on the treponema pallidum tests competition blueprint, pricing analysis of the treponema pallidum tests market, list of service providers in the treponema pallidum tests market and epidemiology study of the treponema pallidum tests market for the duration from 2018 to 2026.
The report offers a comprehensive taxonomy of the treponema pallidum tests market on the basis of treponema pallidum tests type, service providers of treponema pallidum tests and region. On the basis of treponema pallidum tests type, the global treponema pallidum tests market has been segmented into treponemal tests and non-treponemal tests.
On the basis of treponema pallidum tests service provider, the global treponema pallidum tests market has been segmented into hospitals, ambulatory surgical centers, specialty clinics, diagnostic laboratories and academic & research institutes. From a geographical perspective, the treponema pallidum tests market has been segmented into North America, Latin America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA).
Some of the additional questions addressed in this report on the treponema pallidum tests market are-